Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

Botta, Cirino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.176
EU - Europa 3.401
AS - Asia 2.884
Continente sconosciuto - Info sul continente non disponibili 741
SA - Sud America 436
AF - Africa 77
OC - Oceania 11
Totale 12.726
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.967
SG - Singapore 1.143
IT - Italia 1.124
RU - Federazione Russa 1.008
CN - Cina 504
BR - Brasile 335
HK - Hong Kong 321
VN - Vietnam 293
BD - Bangladesh 244
PL - Polonia 239
FR - Francia 190
DE - Germania 172
GB - Regno Unito 146
FI - Finlandia 135
CA - Canada 133
JP - Giappone 95
IN - India 74
IE - Irlanda 68
NL - Olanda 63
AT - Austria 49
AR - Argentina 41
ES - Italia 36
TR - Turchia 35
SE - Svezia 34
IQ - Iraq 31
MX - Messico 29
UZ - Uzbekistan 24
UA - Ucraina 23
EE - Estonia 20
KR - Corea 18
ZA - Sudafrica 18
BE - Belgio 15
CL - Cile 15
CR - Costa Rica 13
EC - Ecuador 13
JM - Giamaica 12
MY - Malesia 12
VE - Venezuela 12
CH - Svizzera 11
PK - Pakistan 11
EG - Egitto 10
CZ - Repubblica Ceca 9
AE - Emirati Arabi Uniti 8
CI - Costa d'Avorio 8
CO - Colombia 8
GR - Grecia 8
ID - Indonesia 8
KE - Kenya 8
MA - Marocco 8
DZ - Algeria 7
PH - Filippine 7
AL - Albania 6
AU - Australia 6
JO - Giordania 6
PY - Paraguay 6
RO - Romania 6
TN - Tunisia 6
AM - Armenia 5
KG - Kirghizistan 5
LT - Lituania 5
NZ - Nuova Zelanda 5
RS - Serbia 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
GT - Guatemala 4
HR - Croazia 4
HU - Ungheria 4
IL - Israele 4
NI - Nicaragua 4
SA - Arabia Saudita 4
TH - Thailandia 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
SV - El Salvador 3
AO - Angola 2
BY - Bielorussia 2
ET - Etiopia 2
IR - Iran 2
KH - Cambogia 2
LK - Sri Lanka 2
MD - Moldavia 2
ME - Montenegro 2
MM - Myanmar 2
NO - Norvegia 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
AD - Andorra 1
AI - Anguilla 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
Totale 11.969
Salva come PNG Salva come JPEG
Città #
Ashburn 832
Singapore 713
San Jose 504
Chandler 375
Hong Kong 288
Fairfield 276
Zgierz 221
Moscow 185
Council Bluffs 175
Palermo 149
Beijing 128
Medford 123
Dallas 120
Los Angeles 120
Wilmington 117
Altamura 114
Lauterbourg 105
Milan 96
Helsinki 95
Tokyo 88
Ho Chi Minh City 82
New York 82
Santa Clara 82
Princeton 79
Houston 77
Lawrence 77
Cambridge 76
Hanoi 76
Rome 67
San Diego 66
Dublin 64
Toronto 63
Buffalo 46
Seattle 46
São Paulo 46
Woodbridge 46
Chicago 45
Hefei 43
London 40
Boardman 34
Nuremberg 34
Frankfurt am Main 32
The Dalles 32
Ann Arbor 29
Lappeenranta 29
Naples 29
Montreal 25
Paris 25
Phoenix 25
Shanghai 23
Vienna 23
Denver 20
Orem 20
Poplar 19
Tallinn 19
Turin 19
Atlanta 18
Bari 18
Catania 18
Florence 17
Brooklyn 16
Stockholm 16
Tashkent 16
Messina 15
Warsaw 15
Brussels 14
Da Nang 14
Haiphong 14
Indianapolis 14
Munich 14
Bologna 13
Chennai 13
Mumbai 13
Porto Alegre 13
Redondo Beach 13
Amsterdam 12
Ankara 12
Kilburn 12
Johannesburg 11
Saint Petersburg 11
Salt Lake City 11
Turku 11
Baghdad 10
Ludwigshafen am Rhein 10
Rio de Janeiro 10
San José 10
Washington 10
Buenos Aires 9
Charlotte 9
Guangzhou 9
Kingston 9
Mexico City 9
Noto 9
Philadelphia 9
San Francisco 9
San Paolo di Civitate 9
Vicenza 9
Abbiategrasso 8
Abidjan 8
Boston 8
Totale 6.992
Salva come PNG Salva come JPEG
Nome #
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation 225
Integrated Multi-Omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution 217
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 207
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 203
Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics 199
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 194
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma 172
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 165
Multi-Omic Profiling of NK Cell Dysfunction and Tumor Immune Escape in Multiple Myeloma Evolution 163
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 161
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 158
BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with Natural Killer cell features 158
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 157
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing 154
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 153
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials 146
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing 146
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it? 146
Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience 146
Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different? 145
Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients 142
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities 140
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 137
High TIM-3 Expression May Contribute to the Functional Impairment of Bone Marrow and Circulating Gamma Delta T Lymphocytes during the Progression of Multiple Myeloma 137
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 133
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells 133
Deciphering the Interplay of Immune Alterations and Microbiome Changes Along Multiple Myeloma Evolution From Premalignant Conditions 132
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report 130
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients 130
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma 130
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant 128
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 126
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy 126
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients 123
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma 122
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 119
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 116
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 115
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 115
Immunologic characterization of COVID-19 patients with hematological cancer 111
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 110
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 110
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma 109
AURKA targeting: a NEAT approach to halt myeloma 109
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 108
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility 106
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 106
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma 104
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 104
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma 104
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 104
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma 103
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 103
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma 101
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response 101
Immunotherapy of colorectal cancer: New perspectives after a long path 99
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 99
POSTER: MM-055 Identification of CD320, CD92, and CD267 as Potential Novel Therapeutic Targets for CAR-T Therapy in Multiple Myeloma 98
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis 98
Could PD-1/PDL1 immune checkpoints be linked to HLA signature? 97
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 97
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm 96
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates 96
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 95
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 95
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) 95
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 92
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes 92
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 92
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer 91
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 90
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab 90
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 89
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 88
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 87
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 87
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials 87
Mouse models of multiple myeloma: Technologic platforms and perspectives 86
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response 85
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 85
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer 85
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma 85
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report 85
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response 85
Single-Cell Transcriptomic Stratification of Multiple Myeloma Reveals Oxidative Stress-Driven Subtypes and Cytogenetic Correlates 84
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 84
P-386 A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells 84
MIR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 84
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma 83
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients 83
miR-22 suppresses DNA ligase III addiction in multiple myeloma 83
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination 80
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients 78
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation 78
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse 78
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies 78
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 77
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 77
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 77
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients 75
Totale 11.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022856 0 131 28 27 23 76 44 43 100 153 61 170
2022/20231.378 109 247 94 112 146 182 21 137 152 18 118 42
2023/2024766 46 116 57 122 68 75 69 56 23 30 10 94
2024/20251.749 55 148 96 157 60 107 132 122 164 176 162 370
2025/20266.449 307 188 318 522 669 855 923 709 700 406 339 513
2026/2027698 425 273 0 0 0 0 0 0 0 0 0 0
Totale 12.726